Home › Research › Cognitive tests and assessment
Statins, cholesterol and cognition at the time of Alzheimer's disease diagnosis: A cross-sectional study from the Swedish registry for cognitive/dementia disorders
Bojana Petek, Minjia Mo, Hong Xu, Jakob Norgren, Minh Tuan Hoang, Marta Villa‐Lopez, Henrike Häbel, Julianna Kele et al.. Journal of Alzheimer s Disease Reports, 2025-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
We included 3074 AD patients (mean age 78.1 years; 59.4% women), of whom 1028 used statins (79.6% simvastatin, 20.4% atorvastatin). Patients with diabetes mellitus, ischemic heart disease, or stroke had greater odds of receiving statins. Older patients had slightly lower odds of receiving any statin at baseline (simvastatin use OR 0.98, 95% CI 0.97-0.99). Simvastatin users had 0.53 points higher MMSE on average at baseline compared to non-users of statins (se 0.23, p = 0.021). Higher low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) levels were associated with higher MMSE in non-users of statins, but not in statin users. Younger AD patients and those with cardiovascular disease were more likely to use statins. Simvastatin use was linked to higher cognitive scores at diagnosis. In non-users, higher LDL-C, TC, and HDL-C levels correlated with better baseline cognitive scores. Longitudinal studies are needed to investigate the effects of statins on cognitive decline in AD.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study of 3,074 participants. In this single point-in-time study, Alzheimer's patients taking simvastatin had slightly higher cognitive scores at diagnosis than non-users, and in non-users higher cholesterol levels went with better scores. Reported effect size: 59.4%; 79.6%; 20.4%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Petek, B., Mo, M., Xu, H., Norgren, J., Hoang, M. T., Villa‐Lopez, M., et al. (2025). Statins, cholesterol and cognition at the time of Alzheimer's disease diagnosis: A cross-sectional study from the Swedish registry for cognitive/dementia disorders. Journal of Alzheimer s Disease Reports. https://doi.org/10.1177/25424823251385903
Vancouver
Petek B, Mo M, Xu H, Norgren J, Hoang MT, Villa‐Lopez M, et al. Statins, cholesterol and cognition at the time of Alzheimer's disease diagnosis: A cross-sectional study from the Swedish registry for cognitive/dementia disorders. Journal of Alzheimer s Disease Reports. 2025. doi:10.1177/25424823251385903. PMID: 41048558.
BibTeX
@article{petek2025-41048558,
author = {Petek, Bojana and Mo, Minjia and Xu, Hong and Norgren, Jakob and Hoang, Minh Tuan and Villa‐Lopez, Marta and Häbel, Henrike and Kele, Julianna and others},
title = {{Statins, cholesterol and cognition at the time of Alzheimer's disease diagnosis: A cross-sectional study from the Swedish registry for cognitive/dementia disorders}},
journal = {Journal of Alzheimer s Disease Reports},
year = {2025},
doi = {10.1177/25424823251385903},
pmid = {41048558},
url = {https://doi.org/10.1177/25424823251385903}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We included 3074 AD patients (mean age 78.1 years; 59.4% women), of whom 1028 used statins (79.6% simvastatin, 20.4% atorvastatin).
- Patients with diabetes mellitus, ischemic heart disease, or stroke had greater odds of receiving statins.
- Older patients had slightly lower odds of receiving any statin at baseline (simvastatin use OR 0.98, 95% CI 0.97-0.99).
- Simvastatin users had 0.53 points higher MMSE on average at baseline compared to non-users of statins (se 0.23, p = 0.021).
- Higher low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) levels were associated with higher MMSE in non-users of statins, but not in statin users.
Why it matters
In this single point-in-time study, Alzheimer's patients taking simvastatin had slightly higher cognitive scores at diagnosis than non-users, and in non-users higher cholesterol levels went with better scores. Because it only looked at one moment, it cannot show whether statins affect cognitive decline over time.
Study details
- Study designcross-sectional
- Participants3,074
- Effect size59.4%; 79.6%; 20.4%
- Evidence strengthModerate
How this study scored 50/100
Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease Reports) |
| Journal's citation record | 0 / 4 | Journal of Alzheimer s Disease Reports: journal h-index 40 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 3,074 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Sara Garcia Ptacek: h-index 39 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Karolinska Institutet: institution h-index 1,477 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41048558) |
| Free to read | 2 / 2 | Free to read |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1177/25424823251385903
- PubMed: 41048558
- Original source →
- Free full text: Journal of Alzheimer s Disease Reports →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Cognitive tests and assessment from nearby years
Also in Cognitive tests and assessment
95 studies in the library are filed under Cognitive tests and assessment with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Cognitive tests and assessment hub.